James Burden, MD
Ophthalmology · Colorado Springs, CONPI 1538180146
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,291 of the $23,612 with a category attached, or 77.5%. Glaukos Corporation accounts for 81.7% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $18,873 and has fallen 96.8% since, to $600 in 2025. Among ophthalmology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 109 payments — averaging $216.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$19K
- AbbVie$872
- Alcon$829
- Lensar, Inc.$772
- Bausch & Lomb Americas Inc.$634
- Bausch & Lomb, A Division Of Bausch Health US, LLC$363
- plus $858 from 9 others
Across 177 payments — averaging $2991.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$530K
What the payments were for
- Consulting fees$18,29177%
- Travel & lodging$8143%
- Food & beverage$4,46219%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 14 | $19,284 |
| AbbVie(2 entities) | 28 | $872 |
| Alcon | 18 | $829 |
| Lensar, Inc. | 2 | $772 |
| Bausch & Lomb Americas Inc. | 8 | $634 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $363 |
| Aerie Pharmaceuticals, Inc. | 8 | $252 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $208 |
| Carl Zeiss Meditec USA, Inc. | 1 | $155 |
| Sun Pharmaceutical Industries Inc. | 7 | $130 |
| Ivantis, Inc | 2 | $33 |
| Shire North American Group Inc | 1 | $24 |
| Novartis | 1 | $22 |
| Kala Pharmaceuticals, Inc. | 1 | $17 |
| Oyster Point Pharma, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iDose$18,291
- LENSAR LASER SYSTEM$693
- STELLARIS$510
- Hydrus Microstent$370
- DURYSTA$242
- iStent Inject Trabecular Micro-Bypass System$171
- iStent inject W$163
- iDose TR$160
- IOLMaster 700$155
- ENVISTA ENVY IOL$147
- ORA System VerifEye$127
- Rhopressa$124
- Rocklatan$124
- Voyager DSLT$119
- LUMIGAN$117
- Tecnis Simplicity$115
- XEN GLAUCOMA TREATMENT SYSTEM$110
- ENVISTA$100
How this compares
$23,612 in reported general payments places this provider in the 90th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 87 | $51,123 |
| RestasisCyclosporine | 40 | $37,608 |
| Prednisolone Acetate | 543 | $35,072 |
| XiidraLifitegrast | 18 | $24,110 |
| CombiganBrimonidine Tartrate/Timolol | 42 | $16,257 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 76 | $15,630 |
| Travoprost | 68 | $14,583 |
| Ketorolac Tromethamine | 404 | $12,644 |
| Latanoprost | 1,066 | $12,137 |
| Brimonidine Tartrate | 204 | $10,971 |
| Brinzolamide | 38 | $9,514 |
| VyzultaLatanoprostene Bunod | 13 | $9,344 |
| Dorzolamide Hcl | 215 | $5,437 |
| Timolol Maleate | 453 | $5,337 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $5,097 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $872 | $104,988169 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $634 | $33,45431 claims |
| AlconSimbrinza | $829 | $5,09711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 262 ophthalmology providers in Colorado.
Other ophthalmology in Colorado Springs
- Steven DeweyColorado Springs$246K
- Charles McMahonColorado Springs$47K
- James LeeColorado Springs$27K
- Matthew ChangColorado Springs$10K
- Ryan RichColorado Springs$7K
- Narine ViruniColorado Springs$6K
- Jason NobleColorado Springs$6K
- John RobertsColorado Springs$4K
- Jackson GoldbergColorado Springs$4K
- Garrett RotaColorado Springs$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.